Drug Profile
Amitifadine
Alternative Names: Amitifadine hydrochloride; DOV-21947; EB-1010Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator DOV Pharmaceutical
- Developer Ethismos Research; Euthymics Bioscience
- Class Antidepressants; Chlorobenzenes; Pyrrolidines; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Depressive disorders; Opioid-related disorders; Pain; Substance-related disorders
- No development reported Alcoholism; Smoking withdrawal
- Discontinued Major depressive disorder; Obesity
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Alcoholism in USA (PO)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Smoking-withdrawal in USA (PO)
- 23 Sep 2020 Ethismos Research plans a phase IIb trials for Smoking withdrawal in USA (PO) (Ethismos Research pipeline, September 2020)